The purpose of the study is to determine if setrusumab can more effectively reduce the frequency of bone fractures, including specific types of fractures in the spine, compared to the standard bisphosphonates. Participants will receive their assigned medication through an infusion, which is a method of delivering fluids or medicine directly into a vein. The study will monitor various factors, such as bone strength measured by dual-energy X-ray absorptiometry, which is a specialized type of X-ray used to check bone density, and the frequency of new bone breaks over time.

Participants in this research have already completed a prior study involving the administration of romosozumab via subcutaneous injection, which is a method of delivering medication through a needle into the fatty layer of the skin just under the surface. The study involves monitoring these individuals over time to observe any adverse events, which are unexpected or undesirable medical occurrences that may happen after using a drug.

Participants in the study will first receive teriparatide for two years. This medication is given as an injection and is sometimes used to help strengthen bones. After this period, participants will receive zoledronic acid, which is administered as an infusion, to further support bone health. The study aims to determine if this treatment plan can effectively reduce the occurrence of fractures, which will be confirmed through imaging techniques like x-rays.

The study will also monitor other aspects such as the total number of fractures, bone pain, quality of life, and functional status over time. These will be assessed using various questionnaires and tools to ensure a comprehensive understanding of the treatment’s impact. The study is expected to last for several years, with regular follow-ups to track the participants’ progress and gather necessary data.

The purpose of the study is to determine the most effective dose of Losartan for patients aged 16 and older with Osteogenesis Imperfecta. Participants will receive the medication over a period of six months. During this time, researchers will monitor changes in a specific marker related to bone health, known as the carboxy-terminal crosslink of type I collagen telopeptide (CTX), to assess how well the treatment is working.

Throughout the study, participants will undergo regular check-ups to track their progress and any changes in their condition. The study will also evaluate other health indicators, such as quality of life and physical function, to gain a comprehensive understanding of the treatment’s impact. This research is important for finding new ways to improve the lives of those living with Osteogenesis Imperfecta.

The purpose of this study is to evaluate the safety and tolerability of administering these stem cells to children and fetuses with severe forms of Brittle Bone Disease. Participants in the study will receive four doses of the BOOST cells, either after birth or both before and after birth. The study will compare the outcomes of these treatments with historical data and untreated controls. The trial aims to understand how safe the treatment is and how well it is tolerated by the participants.

Throughout the study, researchers will monitor the participants for any side effects related to the treatment. They will also track the number of bone fractures, the time it takes for a fracture to occur after the last dose, and changes in bone density and growth. The study will also look at changes in the clinical status of the disease and biochemical markers related to bone turnover. The trial is expected to continue until 2030, providing valuable insights into the potential benefits and risks of using BOOST cells for treating severe Brittle Bone Disease.

The purpose of the study is to evaluate the safety and effectiveness of Setrusumab in reducing the rate of bone fractures in individuals with Osteogenesis Imperfecta. The study is divided into two phases. In the first phase, different doses of Setrusumab will be tested to find the most effective dose. In the second phase, participants will receive either Setrusumab or a placebo to compare the effects. The study will monitor participants over a period of time to see how the treatment affects their bone health and fracture rates.

Participants in the study will receive Setrusumab through an intravenous infusion, which means the medication is given directly into a vein. The study will involve regular visits to the clinic for these infusions and for monitoring the participants’ health and response to the treatment. The goal is to determine if Setrusumab can help reduce the number of fractures and improve the quality of life for those living with Osteogenesis Imperfecta.

Participants in the study will receive either Romosozumab or Bisphosphonates. Romosozumab is given through a subcutaneous injection, which means it is injected under the skin, while Bisphosphonates are typically given as a solution for infusion, meaning they are administered directly into the bloodstream. The study will also involve the use of Calcium and Ergocalciferol (a form of vitamin D) in tablet form to support bone health. The trial will last for a total of 12 months, during which the number of fractures and changes in bone density will be monitored.

Throughout the study, participants will have regular check-ups to monitor their bone health and overall well-being. The study will also measure changes in bone density using a method called DXA (Dual-energy X-ray Absorptiometry), which is a type of imaging test that helps assess bone strength. The goal is to determine if Romosozumab is more effective than Bisphosphonates in reducing fractures and improving bone density in young patients with Osteogenesis Imperfecta.